Menu
Search
|

Menu

Close
X

argenx SE ARGX.OQ (NASDAQ Stock Exchange Global Select Market)

93.12 USD
+1.64 (+1.79%)
As of 4:00 PM EDT
chart
Previous Close 91.48
Open 92.50
Volume 17,549
3m Avg Volume 32,537
Today’s High 93.74
Today’s Low 91.01
52 Week High 103.00
52 Week Low 19.00
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
--
4.34
Price to Cash Flow (TTM)
vs sector
--
22.77
Total Debt to Equity (MRQ)
vs sector
--
17.37
LT Debt to Equity (MRQ)
vs sector
--
12.92
Return on Investment (TTM)
vs sector
--
13.17
Return on Equity (TTM)
vs sector
--
15.14

EXECUTIVE LEADERSHIP

Peter Verhaeghe
Chairman of the Supervisory Board, Since
Salary: --
Bonus: --
Tim Van Hauwermeiren
Chief Executive Officer, Since
Salary: --
Bonus: --
Eric Castaldi
Chief Financial Officer, Since
Salary: --
Bonus: --
Hans de Haard
Chief Scientific Officer, Since
Salary: --
Bonus: --
Debbie Allen
Senior Director, Business Development, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Willemstraat 5
BREDA     4811 AH

Phone: +3176.3030488

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

SPONSORED STORIES